170 related articles for article (PubMed ID: 9452429)
1. Amino acid analogs activate NF-kappaB through redox-dependent IkappaB-alpha degradation by the proteasome without apparent IkappaB-alpha phosphorylation. Consequence on HIV-1 long terminal repeat activation.
Kretz-Remy C; Bates EE; Arrigo AP
J Biol Chem; 1998 Feb; 273(6):3180-91. PubMed ID: 9452429
[TBL] [Abstract][Full Text] [Related]
2. The human immunodeficiency virus type 1 Vpu protein inhibits NF-kappa B activation by interfering with beta TrCP-mediated degradation of Ikappa B.
Bour S; Perrin C; Akari H; Strebel K
J Biol Chem; 2001 May; 276(19):15920-8. PubMed ID: 11278695
[TBL] [Abstract][Full Text] [Related]
3. Hiv-1 Tat can substantially enhance the capacity of NIK to induce IkappaB degradation.
Li X; Josef J; Marasco WA
Biochem Biophys Res Commun; 2001 Aug; 286(3):587-94. PubMed ID: 11511100
[TBL] [Abstract][Full Text] [Related]
4. Proteasome-independent activation of nuclear factor kappaB in cytoplasmic extracts from human endothelial cells by Rickettsia rickettsii.
Sahni SK; Van Antwerp DJ; Eremeeva ME; Silverman DJ; Marder VJ; Sporn LA
Infect Immun; 1998 May; 66(5):1827-33. PubMed ID: 9573057
[TBL] [Abstract][Full Text] [Related]
5. NFkappa B-dependent transcriptional activation during heat shock recovery. Thermolability of the NF-kappaB.Ikappa B complex.
Kretz-Remy C; Munsch B; Arrigo AP
J Biol Chem; 2001 Nov; 276(47):43723-33. PubMed ID: 11559696
[TBL] [Abstract][Full Text] [Related]
6. Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity.
Yin L; Laevsky G; Giardina C
J Biol Chem; 2001 Nov; 276(48):44641-6. PubMed ID: 11572859
[TBL] [Abstract][Full Text] [Related]
7. A caspase-3-like protease is involved in NF-kappaB activation induced by stimulation of N-methyl-D-aspartate receptors in rat striatum.
Qin Z; Wang Y; Chasea TN
Brain Res Mol Brain Res; 2000 Sep; 80(2):111-22. PubMed ID: 11038244
[TBL] [Abstract][Full Text] [Related]
8. Activation of the human immunodeficiency virus long terminal repeat by varicella-zoster virus IE4 protein requires nuclear factor-kappaB and involves both the amino-terminal and the carboxyl-terminal cysteine-rich region.
de Maisieres PD; Baudoux-Tebache L; Merville MP; Rentier B; Bours V; Piette J
J Biol Chem; 1998 May; 273(22):13636-44. PubMed ID: 9593702
[TBL] [Abstract][Full Text] [Related]
9. NO inhibits cytokine-induced iNOS expression and NF-kappaB activation by interfering with phosphorylation and degradation of IkappaB-alpha.
Katsuyama K; Shichiri M; Marumo F; Hirata Y
Arterioscler Thromb Vasc Biol; 1998 Nov; 18(11):1796-802. PubMed ID: 9812920
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor alpha induces expression of genes for matrix degradation in human chondrocyte-like HCS-2/8 cells through activation of NF-kappaB: abrogation of the tumor necrosis factor alpha effect by proteasome inhibitors.
Sakai T; Kambe F; Mitsuyama H; Ishiguro N; Kurokouchi K; Takigawa M; Iwata H; Seo H
J Bone Miner Res; 2001 Jul; 16(7):1272-80. PubMed ID: 11450703
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of IkappaB-alpha and IkappaB-beta proteolysis by calpain inhibitor I blocks nitric oxide synthesis.
Milligan SA; Owens MW; Grisham MB
Arch Biochem Biophys; 1996 Nov; 335(2):388-95. PubMed ID: 8914937
[TBL] [Abstract][Full Text] [Related]
12. 4-Hydroxynonenal prevents NF-kappaB activation and tumor necrosis factor expression by inhibiting IkappaB phosphorylation and subsequent proteolysis.
Page S; Fischer C; Baumgartner B; Haas M; Kreusel U; Loidl G; Hayn M; Ziegler-Heitbrock HW; Neumeier D; Brand K
J Biol Chem; 1999 Apr; 274(17):11611-8. PubMed ID: 10206970
[TBL] [Abstract][Full Text] [Related]
13. Permanent occupancy of the human immunodeficiency virus type 1 enhancer by NF-kappa B is needed for persistent viral replication in monocytes.
Jacqué JM; Fernández B; Arenzana-Seisdedos F; Thomas D; Baleux F; Virelizier JL; Bachelerie F
J Virol; 1996 May; 70(5):2930-8. PubMed ID: 8627768
[TBL] [Abstract][Full Text] [Related]
14. Different mechanisms control signal-induced degradation and basal turnover of the NF-kappaB inhibitor IkappaB alpha in vivo.
Krappmann D; Wulczyn FG; Scheidereit C
EMBO J; 1996 Dec; 15(23):6716-26. PubMed ID: 8978697
[TBL] [Abstract][Full Text] [Related]
15. Transient nuclear factor kappaB (NF-kappaB) activation stimulated by interleukin-1beta may be partly dependent on proteasome activity, but not phosphorylation and ubiquitination of the IkappaBalpha molecule, in C6 glioma cells. Regulation of NF-kappaB linked to chemokine production.
Uehara T; Matsuno J; Kaneko M; Nishiya T; Fujimuro M; Yokosawa H; Nomura Y
J Biol Chem; 1999 May; 274(22):15875-82. PubMed ID: 10336492
[TBL] [Abstract][Full Text] [Related]
16. Activation of NF-kappa B/Rel by Tax involves degradation of I kappa B alpha and is blocked by a proteasome inhibitor.
Maggirwar SB; Harhaj E; Sun SC
Oncogene; 1995 Sep; 11(5):993-8. PubMed ID: 7675460
[TBL] [Abstract][Full Text] [Related]
17. Identification of lysine residues required for signal-induced ubiquitination and degradation of I kappa B-alpha in vivo.
Rodriguez MS; Wright J; Thompson J; Thomas D; Baleux F; Virelizier JL; Hay RT; Arenzana-Seisdedos F
Oncogene; 1996 Jun; 12(11):2425-35. PubMed ID: 8649784
[TBL] [Abstract][Full Text] [Related]
18. IkappaB kinase-independent IkappaBalpha degradation pathway: functional NF-kappaB activity and implications for cancer therapy.
Tergaonkar V; Bottero V; Ikawa M; Li Q; Verma IM
Mol Cell Biol; 2003 Nov; 23(22):8070-83. PubMed ID: 14585967
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibitors induce inhibitory kappa B (I kappa B) kinase activation, I kappa B alpha degradation, and nuclear factor kappa B activation in HT-29 cells.
Németh ZH; Wong HR; Odoms K; Deitch EA; Szabó C; Vizi ES; Haskó G
Mol Pharmacol; 2004 Feb; 65(2):342-9. PubMed ID: 14742676
[TBL] [Abstract][Full Text] [Related]
20. The carboxy-terminus of I kappaB alpha determines susceptibility to degradation by the catalytic core of the proteasome.
Kroll M; Conconi M; Desterro MJ; Marin A; Thomas D; Friguet B; Hay RT; Virelizier JL; Arenzana-Seisdedos F; Rodriguez MS
Oncogene; 1997 Oct; 15(15):1841-50. PubMed ID: 9362451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
